Search PubMed⌕ Search

Biomedical subjects

K U Weithmann

Publications and source records attributed to K U Weithmann.

At least 19 recordsLinked to original sources

Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.

A set of 90 novel 2-(arylsulfonyl)-1,2,3, 4-tetrahydroisoquinoline-3-carboxylates and -hydroxamates as inhibitors of the matrix metalloproteinase human neutrophil collagenase (MMP-8) was designed, synthesized, and investigated by 3D-QSAR techniques (CoMFA, CoMSIA) and X-ray structure analysis. Docking studies of a reference compound are based on crystal structures of MMP-8 complexed with peptidic inhibitors to propose a model of its bioactive conformation. This model was validated by a 1. 7 A X-ray structure of the catalytic domain of MMP-8. The 3D-QSAR models based on a superposition rule derived from these docking studies were validated using conventional and cross-validated r2 values using the leave-one-out method, repeated analyses using two randomly chosen cross-validation groups plus randomization of biological activities. This led to consistent and highly predictive 3D-QSAR models with good correlation coefficients for both CoMFA and CoMSIA, which were found to correspond to experimentally determined MMP-8 catalytic site topology in terms of steric, electrostatic, and hydrophobic complementarity. Subsets selected as smaller training sets using 2D fingerprints and maximum dissimilarity methods resulted in 3D-QSAR models with remarkable correlation coefficients and a high predictive power. This allowed to compensate the weaker zinc binding properties of carboxylates by introducing optimal fitting P1' residues. The final QSAR information agrees with all experimental data for the binding topology and thus provides clear guidelines and accurate activity predictions for novel MMP-8 inhibitors.

Collagenases↗

Effect of uric acid and chemical analogues on oxidation of human low density lipoprotein in vitro.

Oxidative modification of low density lipoprotein (LDL) is implicated in the early development of atherosclerosis. In the present study, attention has been focused toward the potential protective effects of uric acid and purine-based chemical analogues in copper-promoted oxidative changes to human LDL in vitro. Between 5-100 mumol/l uric acid protected LDL from oxidative degradation in a concentration dependent manner. However, 5 mumol/l were not capable of inhibiting the consumption of LDLs natural antioxidative components, alpha-tocopherol and beta-carotene, but led to a more than two-fold prolongation, up to 3 h, of the lag phase before onset of polyunsaturated acid (PUFA) oxidation. 100 mumol/l uric acid, which is still below the human serum level of 300 mumol/l, reduced consumption of alpha-tocopherol and beta-carotene by about 50% and largely suppressed PUFA oxidation for up to 4 h. A more lipophilic series of methyl analogues of uric acid exhibited less activity. Neither 1,3-dimethyl uric acid, nor the 1,3,7- or 1,7- or 3,7-methylated compounds, all at 100 mumol/l, exceeded the antioxidative potential of 10 mumol/l uric acid. At concentrations up to 100 mumol/l xanthine and its analogues lacked virtually any protective effects toward the LDL constituents. In conclusion, the present study indicates that uric acid at concentrations similar to its physiological levels, and also related analogues are able to suppress oxidative degradation of LDL components. In view of the various mechanisms underlying atherogenesis in vivo, the protective effect in terms of modulating redox reactions and oxidative events in the blood or at the arterial wall appears of potential importance.

Antioxidants↗

The cleavage of pro-urokinase type plasminogen activator by stromelysin-1.

Membrane binding of urokinase type plasminogen activator (u-PA) is thought to play a pivotal role in connective tissue remodeling and invasive processes. We compare the ability of different matrix-metalloproteinases involved in connective tissue turnover to cleave pro-urokinase type plasminogen activator between the catalytic domain and the receptor binding part to investigate a potential role for matrix-metalloproteinases in the regulation of membrane-associated proteolytic activity. We employed several forms of human stromelysin-1 (full length, C-truncated, and recombinant catalytic domain), rabbit C-truncated stromelysin-1, the human gelatinases A and B and the human catalytic domain of neutrophil collagenase. The gelatinases and the collagenase did not separate the receptor binding domain of pro-urokinase type plasminogen activator from the catalytic domain, whereas all stromelysin-1 forms cleaved the glutamic acid 143-leucine 144 bond of pro-urokinase type plasminogen activator. This reaction could be inhibited by specific inhibitors of matrix metalloproteinases and was not affected by inhibitors of serine proteinases. The M(r) 31000 cleavage product with leucine 144 as N-terminus displayed no proteolytic activity towards the pro-urokinase type plasminogen activator substrate pyroGlu-Gly-Arg-pNA-HCI (S2444), but it could be activated by an additional treatment with plasmin. Comparison between full length stromelysin-1 and its C-truncated forms, showed that both exhibited the same cleavage properties towards pro-urokinase type plasminogen activator. Thus, the cleavage of pro-urokinase type plasminogen activator by stromelysin-1 is not influenced by the presence or absence of the C-terminal domain. The recombinant catalytic domain of MMP-3 generated pro-urokinase type plasminogen activator, whereas incubation of pro-urokinase type plasminogen activator with the native forms of human or rabbit stromelysin-1 led to a moderate activation of pro-uPA due to an additional cleavage that is catalyzed by a serine proteinase.

Animals↗

Effects of tiaprofenic acid on urinary pyridinium crosslinks in adjuvant arthritic rats: comparison with doxycycline.

OBJECTIVE AND DESIGN: To study the effects of tiaprofenic acid and doxycycline on urinary pyridinium crosslinks and paw swelling in adjuvant arthritic rats, and to gain additional information on the drugs' inhibitory potential vs. in vitro targets, such as enzyme activity of matrix metalloproteinases and cytokine generation. MATERIAL: 124 male Wistar Lewis rats; for the in vitro studies human matrix metalloproteinases and human mononuclear cells were used. TREATMENT: Arthritis was induced by injection of complete Freund adjuvant. Drugs (2, 15, 50 mg tiaprofenic acid/kg; 5, 15, 30 mg doxycycline/kg) were administered daily p.o. until day 21. In the in vitro studies 10-1000 mumoles/l of these drugs were used. METHODS: Urinary levels of pyridinoline and deoxypyridinoline, determined by HPLC/fluorescence, and paw volumes were the measurements in the rat study. In the in vitro studies enzyme activities were assessed using fluorogenic peptide substrates; cytokines were determined by ELISA. RESULTS: On day 21 of disease crosslink excretion was about twofold higher compared to the healthy controls. After administering daily 15 or 30 mg/kg tiaprofenic acid p.o. this increase was almost completely prevented whereas the paw volumes were suppressed by about 50%. Up to 50 mg/kg doxycycline did not display significant suppressive effects on crosslinks and paw volumes. In vitro 50-100 mumol/l of both drugs inhibited the activities of selected metallo-proteinases, but only doxycycline suppressed the generation of IL-1 beta/TNF alpha in human mononuclear cells, whereas tiaprofenic acid was virtually inactive in that model. CONCLUSIONS: In arthritic rats tiaprofenic acid has not only the capability to suppress paw inflammation, but also to prevent with high potency the excretion of pyridinium crosslinks. Doxycycline without inherent antiinflammatory activity does not exhibit such preserving effects on collagen degradation in this model. Thus the mode of action of cartilage protecting drugs within the complex pathogenesis of arthritis will need further elucidation.

Animals↗

Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation.

Leflunomide exerts its effects primarily via the immunomodulating and antiphlogistic activities of its major metabolite A 77 1726. Our investigation in several eicosanoid forming systems revealed that in human white blood cells the metabolite did not cause any alteration on Ca-ionophore stimulated metabolism of membrane bound arachidonic acid to cis-, trans- and epi-LTB4. Thus, the involved enzyme systems phospholipase A2, 5-lipoxygenase and LTA4-hydrolase can be ruled out as a target of the drug. However, in several cellular systems the drug weakly inhibited the generation of 5-HETE and LTB4 from exogenous arachidonic acid, possibly by interfering with the exogenous substrate's access to the 5-lipoxygenase. In order to get information about the cyclooxygenase (COX-2) which is inducible in human PMNL by inflammatory mediators via de novo protein biosynthesis, we activated the cells with LPS for 18 h. A 77 1726 and indomethacin had no influence on the enzyme activity of the newly induced COX-2. However, both drugs in low concentrations were able to blunt the long term activation process resulting in PGE2 generation. In contrast, the prostaglandins generated by constitutive enzymes (COX-1) are probably involved in maintaining vital functions, and their inhibition by indomethacin and other nonsteroidal antiinflammatory drugs (NSAIDs) account for numerous adverse effects, for instance gastric erosion. Our study revealed that leflunomide and A 77 1726 are not to be regarded as COX-1-inhibitors, and thus cannot be associated with the typical adverse effects of the NSAIDs.

Aniline Compounds↗

Annexin proteins PP4 and PP4-X. Comparative characterization of biological activities of placental and recombinant proteins.

The human placental proteins PP4 and PP4-X, belonging to the annexin protein family, were expressed in Escherichia coli at high yield. The proteins were purified to homogeneity. The physicochemical parameters of the recombinant proteins were determined and compared with those of their natural placental counterparts. Except for a minor change in the pI, the proteins appeared to be indistinguishable by several criteria. Both recombinant PP4 and recombinant PP4-X were biologically active in a thromboplastin inhibition test and in a phospholipase A2 inhibition test.

Annexin A5↗

Incorporation of arachidonic, dihomogamma linolenic and eicosapentaenoic acids into cultured V79 cells.

The uptake and distribution of three common dietary polyunsaturated fatty acids was studied using Chinese hamster lung fibroblasts (V79 cells). Treatment of V79 cells with arachidonic (20:4), eicosapentaenoic (20:5) and dihomogammalinolenic (20.3) acids for 24 hr produced a marked uptake of 20:3 and 20:4, both of which were assimilated to a considerably greater degree than 20:5. All polyunsaturated fatty acids were incorporated primarily into phospholipids; however, there were considerable differences in their distribution into individual phospholipid species. Although 20:4 was incorporated primarily into phosphatidylcholine, 20:3 entered largely into phosphatidylethanolamine and phosphatidylglycerol, and 20:5 was distributed about equally between phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol. A marked conversion of 20:3 to 20:4 was found after 24 hr and, in several phospholipids, there was as much derived-radiolabeled 20:4 as there was radiolabeled 20:3. There was little evidence of 20:4 and 20:5 metabolism. V79 cells undergo substantial changes in phospholipid fatty acid composition following supplementation with these polyunsaturated fatty acids; however, these fatty acids are assimilated to different degrees and their distribution among cellular phospholipids is distinct, suggesting incorporation via independent mechanisms.

8,11,14-Eicosatrienoic Acid↗

Stimulatory effects of vascular prostaglandins on the antiaggregatory activities of pentoxifylline acetylsalicylic acid combinations in vitro.

Pentoxifylline, Acetylsalicylic acid (ASA) and particularly both drugs in combination are known as active platelet inhibitors in pharmacological models in vivo. However, rather high amounts of these drugs are necessary to demonstrate inhibitory effects on the aggregation of human platelets in vitro, where no vessel walls are present. Surprisingly, these weak effects could be enhanced by the addition of external prostaglandins (prostacyclin (PGI2) and prostaglandin E1 (PGE1] into the in vitro system. Ternary combinations consisting of pentoxifylline, ASA and PGI2 exhibited the most impressive synergistic effects. Thus our study highlights the contribution of prostaglandins, especially of the natural vascular platelet inhibitor PGI2, for the display of the antiaggregatory potency of such drug combinations.

Alprostadil↗

Substituted 3-phenyl-7H-thiazolo(3,2-b)(1,2,4)triazin-7-ones as antiinflammatory agents with immunomodulating properties.

After structure-activity relationship studies (SAR) on a novel class of substituted thiazolo(3,2-b)(1,2,4)triazin-7-ones, HWA-131 (3-(3,5-di-tert.butyl-4-hydroxyphenyl)-7H-thiazolo(3,2-b)(1,2,4)triaz in-7-one) was selected for incremental pharmacological investigations. This compound was effective in not only preventing, but also curing established arthritic disorders of rats such as adjuvant and type II collagen arthritis as well as those of mice such as chronic graft-versus-host (CGVH) disease, a model for systemic lupus erythematosus (SLE). Further, this non-immunosuppressive drug effectively inhibited the carrageenan-induced paw oedema, attenuated the active Arthus reaction, and demonstrated antierythema as well as antipyretic activity. Part of the antiinflammatory effects of this new compound is most probably related to its antioxidative activity, as well as inhibition of lipoxygenase metabolites. HWA-131's good gastric tolerance may have to do with its limited ability to inhibit the production of cyclooxygenase metabolites. Based on our data, we are sure that HWA-131 will be an effective nonsteroidal antiinflammatory agent, with immunomodulating properties, to combat human autoimmune disorders.

Adjuvants, Immunologic↗

Surprising effects of the sequential administration of pentoxifylline and low dose acetylsalicylic acid on thrombus formation.

The effect of the combined oral administration of pentoxifylline (pof) and low dose acetylsalicylic acid (ASA) was evaluated with the help of the laser-induced thrombosis in rat mesenteric arterioles. Laser-induced thrombosis is inhibited in a dose-dependent way by both drugs. The administration of ASA, either simultaneously with or 1 hour prior to pof, does not show any effects in the laser model. On the contrary, the administration of pof followed 1 h later by ASA not only exhibited a significant effect but also produced a supraadditive inhibition of the laser-induced thrombus formation. Specific investigations concerning the time interval between the administration of both drugs determined that a significant effect can be achieved only after an interval of 30 to 90 minutes (principle of HWA 5112). The striking results could also be shown in diseased animals after sequential chronic administration of pof 1 h prior to ASA. HWA 5112 exhibits significant effects on laser-induced thrombus formation in the following chronic animal models: 1. adjuvant arthritic rats, 10----1 mg/kg for 21 days; 2. spontaneously hypertensive stroke-prone rats, 10----1 mg/kg three times within 24 h; 3. cholesterol-induced atherosclerosis in rabbits, 10----1 mg/kg for 14 days. The reported data clearly demonstrate that the sequential drug administration of first pentoxifylline followed 30 to 90 min later by ASA exhibits a supraadditive antithrombotic effect.

Administration, Oral↗

Topographic aspects of prostacyclin-like and fibrinolytic activity and of biogenic amines in the arterial system of the mini-pig.

Although arteriosclerosis is a systemic disease, it nevertheless exhibits noticeable topographical preference and particularities. The reason for this could be lie with certain biochemical features of the arterial wall. We therefore examined prostacyclin-like and fibrinolytic activity in mini-pigs, as well as the concentration of various biogenic amines in the thoracic and abdominal aorta, in coronary arteries and in the carotid and femoral artery. There was a similar behaviour between PG I2-like release and biogenic amines in the different arteries, whereas fibrinolytic activity behaved differently in some cases. In the femoral artery particularly low fibrinolytic activity was confronted by a particularly high level of PG I2-like activity and biogenic amines, while the reverse was the case in the abdominal aorta. In older animals PG I2-like activity considerably decreased.

Animals↗

Biochemical and pharmacological effects of dipyrone and its metabolites in model systems related to arachidonic acid cascade.

The metabolites of dipyrone (metamizol, Novalgin) were compared with appropriate standard drugs for their influences on the pathways of the arachidonic acid metabolism. The drugs in this study had no significant effects on the lipoxygenase pathway in human neutrophils in vitro. The dipyrone metabolites 4-methylaminoantipyrine (MAAP) and 4-aminoantipyrine (AAP) inhibited prostaglandin synthesis in the 10(-3) to 10(-4) mol/l range thus being comparable to acetylsalicylic acid (ASA), whereas the two additional metabolites 4-acetylaminoantipyrine (AAAP) and 4-formylaminoantipyrine (FAAP) were practically inactive. This result is in accordance with the effects of the metabolites on the formation of oedema in the arthritis rat model, and supports published data showing that MAAP and AAP are the metabolites responsible for the clinical effects of dipyrone. Further systems in our study depending at least partially on the prostaglandin pathway were the release of antiaggregatory activity from rat aortae in vitro and the aggregation of human platelets induced by arachidonic acid in vitro. MAAP exhibits antiaggregatory activity (IC50 5 x 10(-6) mol/l), whereas the inhibitory effect on the vascular antiaggregatory release is much weaker. Compared to normals platelet aggregability ex vivo is enhanced in arthritic rats, but could significantly be lowered again by treatment of the rats with MAAP. A further system studied was the release of 6-keto-PGF1 alpha from rat mucosa in vitro and ex vivo. In vitro there is inhibition to be found with MAAP as well as with ASA. Ex vivo, however, dipyrone or MAAP slightly stimulates mucosal 6-keto-PGF1 alpha rather than inhibiting it, whereas ASA exerts inhibition, as expected.(ABSTRACT TRUNCATED AT 250 WORDS)

6-Ketoprostaglandin F1 alpha↗

Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP.

1. Inhibition of platelet aggregation in vitro by pentoxifylline is rather weak, requiring about 1 mM pentoxifylline. Ex vivo, however, 15 mg/kg p.o. pentoxifylline exerts an enhanced release of prostacyclin-(PGI2)-like antiaggregatory activity from rat aortas. 2. Rat aorta incubated in vitro with 1 microM pentoxifylline releases antiaggregatory activity in a similar manner. The conversion of prostaglandin H2 to PGI2-like activity which is catalyzed by vascular microsomes, also is drastically stimulated in vitro by addition of 1 microM pentoxifylline. 3. Despite its inhibitory effect on platelet cyclic AMP-phosphodiesterase pentoxifylline in vitro without PGI2 has no essential effect on cyclic AMP levels in human platelets. However, in presence of PGI2, release of which probably is increased by pentoxifylline cyclic AMP level as well as inhibition of aggregation are enhanced by pentoxifylline above the effects of PGI2 itself.

Animals↗

HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.

The new pyrimido-isoquinoline compound HL 725 is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine. The aggregation induced by 0,5 mM arachidonic acid is inhibited about 50% with 50 pM HL 725. Thus the potency of HL 725 is higher than that of prostacyclin, the most active natural inhibitor of aggregation. We hypothesize that HL 725 inhibits the enzymatic degradation of cyclic adenosine 3', 5'-monophosphate (cAMP) in the platelets. In accordance with this proposal is the strong inhibitory action on cAMP phosphodiesterase extracted from human platelets. About 250 pM HL 725 inhibited 50% of the activity of this enzyme at a substrate concentration of 0.5 microM. A marked elevation of cAMP levels in human platelets could be demonstrated after incubation in vitro with 100 nM HL 725.

3',5'-Cyclic-AMP Phosphodiesterases↗